Novartis (NYSE: NVS) stock fell 4% in premarket trading Wednesday after the Swiss pharmaceutical company reported worse-than-expected core earnings for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE